Fig. 5: TBG targeting and anti-TB efficacy of manSNI in vivo.
a Schematic illustration of manSNI-mediated anti-TB therapy in vivo. Fluorescence imaging (b) and quantitative analysis of fluorescence intensity (c) of lungs isolated from mice at different time points after the intravenous administration of SN and manSNI (n = 3 independent mouse). d Tissue-clearing and 3D fluorescence imaging of lung tissues (small arrows: TBG). e 3D fluorescence images of lung tissues from TBG-bearing mice after receiving SN or manSNI via intravenous administration 72 h. f Correlation of manSNI accumulation with Mecherry-BCG density within TBG. g Fluorescence images of Mcherry-BCG-infected lung tissues isolated from mice after different treatments. Treatments: mice with Mcherry-BCG-infected TB (21 days after infection) were intravenously injected with saline, SN, manSN, and manSNI. At 24 and 72 h post-injection, the entire chest area of the mice was either sonicated for 15 min (1.5 W/cm2) or not sonicated. In each group, n = 6 mice. Colony coating (h) and CFU counting (i) of BCG harvested from the lung tissues of TB mice on day 21 (n = 3 independent mouse). j H&E staining of the lung tissues isolated from TB mice on day 21. AFB staining (k) and quantification of positive area (l) of the lung tissues isolated from TB mice on day 21 (n = 3 independent mouse). For c, i and l data are shown as the mean ± s.d., statistical significance was calculated via one-way ANOVA with Tukey’s post hoc test. Experiments were repeated independently three times with similar results in j and k and a representative result is shown for each. a.u. arbitrary units, FL fluorescence.
